Ushio Jun, Kanno Atsushi, Ikeda Eriko, Ando Kozue, Nagai Hiroki, Miwata Tetsurou, Kawasaki Yuki, Tada Yamato, Yokoyama Kensuke, Numao Norikatsu, Tamada Kiichi, Lefor Alan Kawarai, Yamamoto Hironori
Department of Medicine, Division of Gastroenterology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan.
Department of Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan.
Diagnostics (Basel). 2021 Mar 20;11(3):562. doi: 10.3390/diagnostics11030562.
The number of new cases of pancreatic ductal adenocarcinoma is increasing with a cumulative total of 495,773 cases worldwide, making it the fourteenth most common malignancy. However, it accounts for 466,003 deaths per year and is the seventh leading cause of cancer deaths. Regional differences in the number of patients with pancreatic ductal adenocarcinoma appear to reflect differences in medical care, as well as racial differences. Compared to the prevalence of other organ cancers in Japan, pancreatic ductal adenocarcinoma ranks seventh based on the number of patients, eighth based on morbidity, and fourth based on the number of deaths, with a continuing increase in the mortality rate. Risk factors for developing pancreatic ductal adenocarcinoma include family history, genetic disorders, diabetes, chronic pancreatitis, and intraductal papillary mucinous neoplasms. An issue that hinders improvement in the prognosis of patients with pancreatic ductal adenocarcinoma is the development of a strategy to identify patients with these risk factors to facilitate detection of the disease at a stage when intervention will improve survival.
胰腺导管腺癌的新发病例数正在增加,全球累计病例数达495,773例,使其成为第十四大常见恶性肿瘤。然而,它每年导致466,003人死亡,是癌症死亡的第七大主要原因。胰腺导管腺癌患者数量的地区差异似乎反映了医疗保健方面的差异以及种族差异。与日本其他器官癌症的患病率相比,胰腺导管腺癌患者数量排名第七,发病率排名第八,死亡人数排名第四,死亡率持续上升。发生胰腺导管腺癌的风险因素包括家族史、遗传疾病、糖尿病、慢性胰腺炎和导管内乳头状黏液性肿瘤。阻碍胰腺导管腺癌患者预后改善的一个问题是制定一种策略,以识别具有这些风险因素的患者,以便在干预可提高生存率的阶段促进疾病的检测。